Kymera Therapeutics [KYMR] vs Madrigal [MDGL] Detailed Stock Comparison
Kymera Therapeutics
NASDAQ
Loading...
Madrigal
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Kymera Therapeutics wins in 7 metrics, Madrigal wins in 10 metrics, with 0 ties. Madrigal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Kymera Therapeutics | Madrigal | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -13.94 | -17.67 | Madrigal |
| Price-to-Book Ratio | 3.09 | 12.12 | Kymera Therapeutics |
| Debt-to-Equity Ratio | 8.82 | 17.81 | Kymera Therapeutics |
| PEG Ratio | -0.22 | 0.24 | Kymera Therapeutics |
| EV/EBITDA | -8.08 | -25.25 | Madrigal |
| Profit Margin (TTM) | 0.00% | -54.68% | Kymera Therapeutics |
| Operating Margin (TTM) | -736.82% | -22.18% | Madrigal |
| Return on Equity | -33.26% | -36.30% | Kymera Therapeutics |
| Return on Assets (TTM) | -19.92% | -18.31% | Madrigal |
| Free Cash Flow (TTM) | $-207.34M | $-462.03M | Kymera Therapeutics |
| 1-Year Return | -10.86% | 61.07% | Madrigal |
| Price-to-Sales Ratio (TTM) | 68.07 | 16.41 | Madrigal |
| Enterprise Value | $2.46B | $7.79B | Madrigal |
| EV/Revenue Ratio | 55.11 | 15.10 | Madrigal |
| Gross Profit Margin (TTM) | N/A | 95.74% | N/A |
| Revenue per Share (TTM) | $1 | $23 | Madrigal |
| Earnings per Share (Diluted) | $-3.49 | $-12.64 | Kymera Therapeutics |
| Beta (Stock Volatility) | 2.18 | -1.03 | Madrigal |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Kymera Therapeutics vs Madrigal Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | 3.52% | 2.50% | -5.65% | 41.35% | 15.70% | 4.16% |
| Madrigal | 1.99% | 9.62% | 23.01% | 46.84% | 21.07% | 29.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | -10.86% | 37.17% | 27.97% | 28.05% | 28.05% | 28.05% |
| Madrigal | 61.07% | 481.06% | 281.74% | 464.62% | 295.62% | 18.08% |
Performance & Financial Health Analysis: Kymera Therapeutics vs Madrigal
| Metric | KYMR | MDGL |
|---|---|---|
| Market Information | ||
| Market Cap | $3.04B | $8.46B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 829,050 | 451,780 |
| 90 Day Avg. Volume | 643,953 | 438,397 |
| Last Close | $44.09 | $415.18 |
| 52 Week Range | $19.44 - $53.27 | $200.63 - $419.99 |
| % from 52W High | -17.23% | -1.15% |
| All-Time High | $91.92 (Dec 28, 2020) | $419.99 (Aug 22, 2025) |
| % from All-Time High | -52.03% | -1.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.55% | 13.54% |
| Quarterly Earnings Growth | -0.55% | 13.54% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.55% |
| Operating Margin (TTM) | -7.37% | -0.22% |
| Return on Equity (TTM) | -0.33% | -0.36% |
| Debt to Equity (MRQ) | 8.82 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.77 | $31.32 |
| Cash per Share (MRQ) | $9.31 | $35.76 |
| Operating Cash Flow (TTM) | $-251,008,000 | $-307,412,992 |
| Levered Free Cash Flow (TTM) | $-153,841,376 | $-219,782,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Kymera Therapeutics vs Madrigal
| Metric | KYMR | MDGL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -13.94 | -17.67 |
| Forward P/E | -13.69 | -27.19 |
| PEG Ratio | -0.22 | 0.24 |
| Price to Sales (TTM) | 68.07 | 16.41 |
| Price to Book (MRQ) | 3.09 | 12.12 |
| Market Capitalization | ||
| Market Capitalization | $3.04B | $8.46B |
| Enterprise Value | $2.46B | $7.79B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 55.11 | 15.10 |
| Enterprise to EBITDA | -8.08 | -25.25 |
| Risk & Other Metrics | ||
| Beta | 2.18 | -1.03 |
| Book Value per Share (MRQ) | $13.77 | $31.32 |
Financial Statements Comparison: Kymera Therapeutics vs Madrigal
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | KYMR | MDGL |
|---|---|---|
| Revenue/Sales | $11.48M | $137.25M |
| Cost of Goods Sold | N/A | $4.51M |
| Gross Profit | N/A | $132.74M |
| Research & Development | $78.39M | $44.17M |
| Operating Income (EBIT) | $-84.56M | $-79.31M |
| EBITDA | $-74.42M | $-69.56M |
| Pre-Tax Income | $-76.61M | $-73.24M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-76.61M | $-73.24M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | KYMR | MDGL |
|---|---|---|
| Cash & Equivalents | $89.97M | $183.65M |
| Total Current Assets | $500.95M | $987.98M |
| Total Current Liabilities | $58.99M | $167.24M |
| Long-Term Debt | $73.09M | $118.76M |
| Total Shareholders Equity | $786.23M | $710.64M |
| Retained Earnings | $-820.19M | $-1.88B |
| Property, Plant & Equipment | $18.88M | $4.01M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | KYMR | MDGL |
|---|---|---|
| Operating Cash Flow | $-67.71M | $-81.76M |
| Capital Expenditures | $-467,000 | $0 |
| Free Cash Flow | $-79.62M | $-88.89M |
| Debt Repayment | $-277,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | KYMR | MDGL |
|---|---|---|
| Shares Short | 7.75M | 3.98M |
| Short Ratio | 12.29 | 11.26 |
| Short % of Float | 0.14% | 0.21% |
| Average Daily Volume (10 Day) | 829,050 | 451,780 |
| Average Daily Volume (90 Day) | 643,953 | 438,397 |
| Shares Outstanding | 64.89M | 22.00M |
| Float Shares | 46.96M | 11.01M |
| % Held by Insiders | 0.02% | 0.08% |
| % Held by Institutions | 1.10% | 1.07% |
Dividend Analysis & Yield Comparison: Kymera Therapeutics vs Madrigal
| Metric | KYMR | MDGL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |